GHK-Cu Stress-Study Analytical Record: RP-HPLC, MS, and Reported Conditions

Research use only. This article does not provide medical, veterinary, dosing, administration, safety, or outcome guidance.

What Badenhorst et al. examined

Badenhorst, Svirskis, and Wu reported a physicochemical study of glycyl-L-histidyl-L-lysine-copper (GHK-Cu) using a stability-indicating reversed-phase HPLC method. Their abstract also reports mass-spectrometry work on degradation products. The paper’s title refers to native glycyl-L-histidyl-L-lysine tripeptide, while its abstract identifies the GHK-Cu material; that wording should remain attached to this source rather than be treated as a description of every GHK-Cu record.

The authors measured solubility and distribution coefficients, then examined the material under basic, oxidative, and acidic stress conditions. They reported hydrolytic cleavage under basic and oxidative stress and a lesser response under acidic stress, with first-order degradation profiles in the conditions described. The source also reports water and pH 4.5-7.4 buffer observations for at least two weeks at 60 C. These are observations from the stated study conditions, not stability results for another preparation, storage arrangement, or batch.

Analytical readouts reported in the study

The study paired reversed-phase HPLC with mass spectrometry and identified three degradation products, including histidine. Its compatibility comparison concerned the formulation components named by the authors: they reported compatibility with Span 60-based niosomes and lower stability in the presence of the negatively charged lipid dicetyl phosphate. The paper does not report the composition, analytical result, or handling properties of the catalogue material linked above.

The reported methods, stressors, media, time period, and formulation components are part of one experimental record. A different analytical document or study needs its own stated material, method, and conditions before its result can be compared with this work.

Related GHK-Cu source

GHK-Cu: Copper-Complex Source Methods and Documentation Review covers a separate study of copper-complex equilibria and spectroscopy. That study uses different materials and methods from the stress and degradation work described here.

What the preformulation paper actually records

Badenhorst, Svirskis, and Wu describe a preformulation study of native glycyl-L-histidyl-L-lysine (GHK) for a dermal-delivery research context. The paper is organized around physicochemical characterization rather than a clinical or catalogue-batch comparison. Its reported work includes reversed-phase HPLC and mass-spectrometric characterization under the conditions stated by the authors, together with observations relevant to formulation development. The study’s analyte, preparation, instrument settings, and storage or stress conditions must be read from the paper itself; a short abstract cannot supply fields that the full method does not report.

Keep stress observations attached to conditions

A stress-study observation is meaningful only with its stressor, solvent or matrix, temperature, duration, sampling point, and analytical readout. If one of those fields is absent from a summary, mark it unreported. Do not turn a reported chromatographic change into a general shelf-life statement, and do not treat a mass-spectrometry signal as proof that every vial or salt form has the same composition. The paper’s purpose and experimental boundary are narrower than a universal specification.

Terminology and catalogue boundaries

GHK is a tripeptide sequence, while GHK-Cu refers to a copper-associated material designation used in research and commercial records. Public chemical databases can help normalize names and identifiers, but a database entry is not an assay of the catalogue material. The related Peptides Bio GHK-Cu 50mg page is a listing record; it does not become the test article in PMID 25384620 merely because the names are similar. Record the publication material, the database terminology, and the catalogue item as three separate evidence objects.

How to write a bounded result

A traceable summary states the technique, the sample or analyte named by the authors, the reported condition, and the exact observation. It then states what was not measured: for example, no external lot identity, no independent release specification, and no human or veterinary outcome. This format lets a reviewer reproduce the citation without implying that the preformulation record validates a future batch or a different formulation.

Research-only boundary: The cited study is an analytical preformulation record. It is not a dosing instruction, administration guide, safety guarantee, therapeutic claim, or purchasing recommendation.

Cross-check the publication metadata

Europe PMC indexes PMID 25384620 as a 2016 journal article in Pharmaceutical Development and Technology, volume 21, issue 2, pages 152-160, with DOI 10.3109/10837450.2014.979944. These bibliographic fields help prevent a preprint, editorial, or similarly named dermal-delivery paper from being substituted for the cited record. Bibliographic confirmation is useful, but it does not add experimental detail beyond what the paper reports.

Do not collapse characterization into efficacy

RP-HPLC retention or a mass-spectrometric signal can be part of a physicochemical record. They are not, by themselves, evidence of a wound-healing, anti-aging, or other outcome in people or animals. Keep the analytical observation beside its sample and method, and keep any biological claim in the source that actually measured it. The related catalogue material remains a separate documentation object.

Record the article DOI and database identifiers with the analytical notes, then keep the publication material and the catalogue material in separate fields. This simple separation prevents a characterization paper from being read as a release document for a later batch.